Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

sanofi-aventis healthcare pty ltd t/a sanofi consumer healthcare - ubidecarenone -

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

biogen australia pty ltd - nusinersen heptadecasodium, quantity: 12.6 mg (equivalent: nusinersen, qty 12 mg) - injection, solution - excipient ingredients: calcium chloride dihydrate; sodium hydroxide; water for injections; potassium chloride; sodium chloride; monobasic sodium phosphate dihydrate; hydrochloric acid; dibasic sodium phosphate; magnesium chloride hexahydrate - spinraza is indicated for the treatment of 5q spinal muscular atrophy (sma).

Írsko - angličtina - HPRA (Health Products Regulatory Authority)

janssen-cilag ltd - haloperidol decanoate - solution for injection - 100 mg/ml - haloperidol

Írsko - angličtina - HPRA (Health Products Regulatory Authority)

janssen-cilag ltd - haloperidol decanoate - solution for injection - 50 milligram(s)/millilitre - butyrophenone derivatives; haloperidol

Spojené štáty - angličtina - NLM (National Library of Medicine)

tya pharmaceuticals - haloperidol decanoate (unii: ac20pj4101) (haloperidol - unii:j6292f8l3d) - haloperidol 100 mg in 1 ml - haloperidol decanoate injection is indicated for the treatment of schizophrenic patients who require prolonged parenteral antipsychotic therapy. since the pharmacologic and clinical actions of haloperidol decanoate injection are attributed to haloperidol as the active medication, and additional information are those of haloperidol, modified only to reflect the prolonged action. , , contraindicationswarnings haloperidol is contraindicated in severe toxic central nervous system depression or comatose states from any cause and in individuals who are hypersensitive to this drug or have parkinson’s disease.

Spojené štáty - angličtina - NLM (National Library of Medicine)

teva parenteral medicines, inc. - haloperidol decanoate (unii: ac20pj4101) (haloperidol - unii:j6292f8l3d) - haloperidol 50 mg in 1 ml - haloperidol decanoate injection 50 mg/ml and haloperidol decanoate injection 100 mg/ml are indicated for the treatment of schizophrenic patients who require prolonged parenteral antipsychotic therapy. since the pharmacologic and clinical actions of haloperidol decanoate injection 50 mg/ml and haloperidol decanoate injection 100 mg/ml are attributed to haloperidol as the active medication, contraindications, warnings, and additional information are those of haloperidol, modified only to reflect the prolonged action. haloperidol is contraindicated in severe toxic central nervous system depression or comatose states from any cause and in individuals who are hypersensitive to this drug or have parkinson's disease.

Spojené kráľovstvo - angličtina - MHRA (Medicines & Healthcare Products Regulatory Agency)

essential pharma ltd - haloperidol decanoate - solution for injection - 50mg/1ml

Spojené kráľovstvo - angličtina - MHRA (Medicines & Healthcare Products Regulatory Agency)

essential pharma ltd - haloperidol decanoate - solution for injection - 100mg/1ml

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

lundbeck australia pty ltd - flupentixol decanoate, quantity: 20 mg - injection, solution - excipient ingredients: fractionated coconut oil - flupenthixol is indicated for the maintenance treatment of chronic schizophrenia and other related chronic psychoses, in patients intolerant of and/or refractory to other depot preparations. flupenthixol is intended for maintenance therapy and not for short-term use ( less than 3 months).

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

lundbeck australia pty ltd - flupentixol decanoate, quantity: 20 mg - injection, solution - excipient ingredients: fractionated coconut oil - flupenthixol is indicated for the maintenance treatment of chronic schizophrenia and other related chronic psychoses, in patients intolerant of and/or refractory to other depot preparations. flupenthixol is intended for maintenance therapy and not for short-term use (less than 3 months). flupenthixol is indicated for the maintenance treatment of chronic schizophrenia and other related chronic psychoses, in patients intolerant of and/or refractory to other depot preparations. flupenthixol is intended for maintenance therapy and not for short term use (less than 3 months).